Furthermore, talazoparib is being investigated in combination with gemtuzumab ozogamicin (GO), an anti-CD33 antibody conjugated to calicheamicin, recently approved by the FDA for treating CD33-positive AML (NCT04207190) [154]. The gene discussed is CD33; the disease is acute myeloid leukemia.